Three different premixed combinations of biphasic insulin aspart – comparison of the efficacy and safety in a randomized controlled clinical trial in subjects with type 2 diabetes

Cucinotta, Domenico; Smirnova, Olga Mikhailovna; Js, Christiansen; Kanc, Karin; Devehat, C. Le; Wojciechowska, Małgorzata; Torre, Martín López de la; Liebl, Andreas

doi:10.1111/j.1463-1326.2009.01035.x

Cited by 25 publications

(25 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a 12-week randomized study of insulin-naive Chinese patients with type 2 diabetes, LM50 twice daily for 12 weeks was associated with better glycemic control (HbA1c 5.5 ± 1.4% vs 6.5 ± 1.5%, p < 0.05) and more rapid achievement of target blood glucose levels (12.6 ± 3.6 days vs 22.3 ± 4.7 days, p < 0.05) than LM25 twice daily, without an increase in hypoglycemic episodes [22]. Another randomized clinical trial found that mid-mix biphasic insulin aspartate (BIAsp) three times daily also improved glycemic control to a greater extent than low-mix BIAsp twice daily without a causing a higher incidence of hypoglycemia [23]. In contrast, an open-label randomized study found that switching to LM50 from LM25 in 302 patients with type 2 diabetes who had not achieved adequate glycemic control did not clearly produce an improvement in overall glycemic control in terms of endpoints similar to those used in the current study [24].…”

Section: Discussionmentioning

confidence: 99%

Insulin lispro 25/75 and insulin lispro 50/50 as starter insulin in Japanese patients with type 2 diabetes: subanalysis of the CLASSIFY randomized trial

Watada

Imori

et al. 2017

Endocr J

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Insulin lispro 25/75 and insulin lispro 50/50 as starter insulin in Japanese patients with type 2 diabetes: subanalysis of the CLASSIFY randomized trial

Watada

Imori

et al. 2017

Endocr J

View full text Add to dashboard Cite

“…Tsukuda et al 4) reported that BG profile after thrice daily injections of BIAsp70 in patients with T2DM was close to that of healthy subjects. However, the majority of the papers that we referred 3,5,6) have demonstrated that use of BIAsp70 as pre-dinner insulin failed to control nighttime glycemia in some cases. They concluded that different combination of biphasic formulations, such as BIAsp70 before breakfast and lunch and BIAsp30 (30% rapid acting and 70% intermediateacting insulin) before dinner, could control glycemia in patients with unsatisfactory BG levels during nighttime and before breakfast.…”

Section: Discussionmentioning

confidence: 99%

“…There is no clear evidence that twice daily regimens using such premixed preparations in young children are less effective for glycemic control, but some evidence shows poorer glycemic control are appeared when it is used in adolescents 9) . Thrice daily injections of high ratio of Ra biphasic insulin analog, such as BIAsp70, have been reported it could replicate physiological bolus and basal pattern on MDI in adults with T2DM [4][5][6] . Tsukuda et al 4) reported that BG profile after thrice daily injections of BIAsp70 in patients with T2DM was close to that of healthy subjects.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Potential for BIAsp70 to Control Postprandial Hyperglycemia in Children with Type 1 Diabetes Mellitus

Urakami

Kuwabara

Habu

et al. 2014

Nichidai Igaku Zasshi

View full text Add to dashboard Cite

Objective: To examine the potential for mealtime boluses of biphasic insulin aspart 70 (BIAsp70); 70% rapidacting fraction and 30% intermediate-acting fraction, in reducing the subsequent increase of blood glucose (BG) after a meal rich in protein and fat.Materials and Methods: The subjects were 25 children with type 1 diabetes mellitus (T1DM) who were currently on multiple daily injections. They were divided into two groups based on lunchtime insulin use, i.e. 20 using rapid acting insulin (group Ra) and 5 using BIAsp70 (group BIAsp70). The BG profiles before and up to 6 hours after taking the two types of lunch were compared between the two groups.Results: The postprandial changes of the BG concentrations (Δ%) 1, 2, 3 and 6 hours after Japanese-style meals in the Ra group were 14, 15, 10 and −8%, and those in the BIAsp70 group were −8, 62, −11 and −30%. The Δ% reduction after 3 and 6 hours were greater in the BIAsp70 group than in the Ra group. On the other hand, the Δ% after the protein-and fat-rich meals in the Ra group after 1, 2, 3 and 6 hours were 97, 63, 49 and 34%, compared with 69, 43, 40 and −24%, respectively, in the BIAsp70 group. BG decreased to below the preprandial level and the Δ% was negative after 6 hours in the BIAsp70 group compared with the Ra group.Conclusions: Mealtime boluses of BIAsp70 might be useful to control postprandial glycemia after 3 hours or more, in children with T1DM, especially after a protein-and fat-rich meal.

show abstract

“…Chadha showed data from two recent studies demonstrating clear benefits of high ratio premixed insulins on postprandial glucose profile and overall metabolic control in people with type 2 diabetes. 51,52 Keynote Lecture: The Selfish Brain-Conflicting Interests Between Brain and Body Can Help to Explain Why Diets Often Fail Achim Peters, Luebeck, Germany…”

Section: Monitoring and Treatment Of Pphmentioning

confidence: 99%

6^thAnnual Symposium on Self-Monitoring of Blood Glucose (SMBG) Applications and Beyond, April 25–27, 2013, Riga, Latvia

Alzaid

Schlaeger²,

Hinzmann³

2013

Diabetes Technology & Therapeutics

View full text Add to dashboard Cite

International experts in the fields of diabetes, diabetes technology, endocrinology, and pediatrics gathered for the 6 th Annual Symposium on Self-Monitoring of Blood Glucose (SMBG) Applications and beyond. The aim of this meeting was to continue setting up a global network of experts in this field and provide an international platform for exchange of ideas to improve life for people with diabetes. The 2013 meeting comprised a comprehensive scientific program, parallel interactive workshops, and two keynote lectures. All these discussions were intended to help identify gaps and areas where further scientific work and clinical studies are warranted. Opening Lecture: News from the World of DiabetesSatish Garg, University of Colorado Denver, Aurora, Colorado Drugs can't do it alone, we need technology too S atish Garg, in his opening lecture, gave insights into the status of diabetes care in general, described the direction of the ongoing diabetes research, and unveiled exciting technological advances coming our way in the near future. He argued that diabetes technology has a major contribution to make on the quality of life and the day-to-day interaction between patient and disease. He put forward a poignant question, saying that we are almost spoiled for choice by the number of antidiabetes agents currently available to treat diabetes, but has that changed patient outcome?Garg advocated that drugs cannot do it alone and that there is a clear gap in the management of diabetes that may be filled in by diabetes-related technologies. Diabetes: uncontrollable costGarg presented recently published data that show the cost of diabetes alone amounts to a staggering $245 billion per year in the United States.1 This figure is expected to rise in the future. Almost one-third of people with diabetes belong to the elderly age group (above 65 years of age), meaning that most individuals have been systematically excluded from research trials and clinical studies. Garg made a timely and passionate plea that elderly people with diabetes must not be left out of the diabetes research agenda.A closer examination of the cost of diabetes expenditure reveals that 80% of the money is used to pay for services and late complications. Eight percent of the total expenditure is used for diabetes technology. Garg suggested that people with diabetes should be cared for from the outset to reduce the expense incurred due to late complications. Glycated hemoglobin and hypoglycemia as measures of healthcare outcomeRecent clinical data of 25,000 people with type 1 diabetes attending 67 leading diabetes centers across the United States were presented by Garg. The T1D Exchange Study 2 is an observational study that showed several interesting findings. First, despite all existing efforts, the pursuit of the target glycated hemoglobin (HbA1c) level remains elusive for many people with diabetes across the United States. Second, the incidence of hypoglycemia remains a major concern for many people with diabetes, especially the elderly. Another and...

show abstract

Three different premixed combinations of biphasic insulin aspart – comparison of the efficacy and safety in a randomized controlled clinical trial in subjects with type 2 diabetes

Abstract: Glycaemic control improved with BIAsp 50 t.i.d. without higher incidence of hypoglycaemia compared with BIAsp 30 b.i.d.; with BIAsp 70 t.i.d. lower PG levels from lunch to 02.00 hours, but more hypoglycaemic episodes were obtained compared with BIAsp 30 b.i.d.

Cited by 25 publications

References 10 publications

Insulin lispro 25/75 and insulin lispro 50/50 as starter insulin in Japanese patients with type 2 diabetes: subanalysis of the CLASSIFY randomized trial

Insulin lispro 25/75 and insulin lispro 50/50 as starter insulin in Japanese patients with type 2 diabetes: subanalysis of the CLASSIFY randomized trial

Potential for BIAsp70 to Control Postprandial Hyperglycemia in Children with Type 1 Diabetes Mellitus

6^thAnnual Symposium on Self-Monitoring of Blood Glucose (SMBG) Applications and Beyond, April 25–27, 2013, Riga, Latvia

Contact Info

Product

Resources

About

Three different premixed combinations of biphasic insulin aspart – comparison of the efficacy and safety in a randomized controlled clinical trial in subjects with type 2 diabetes

Abstract: Glycaemic control improved with BIAsp 50 t.i.d. without higher incidence of hypoglycaemia compared with BIAsp 30 b.i.d.; with BIAsp 70 t.i.d. lower PG levels from lunch to 02.00 hours, but more hypoglycaemic episodes were obtained compared with BIAsp 30 b.i.d.

Cited by 25 publications

References 10 publications

Insulin lispro 25/75 and insulin lispro 50/50 as starter insulin in Japanese patients with type 2 diabetes: subanalysis of the CLASSIFY randomized trial

Insulin lispro 25/75 and insulin lispro 50/50 as starter insulin in Japanese patients with type 2 diabetes: subanalysis of the CLASSIFY randomized trial

Potential for BIAsp70 to Control Postprandial Hyperglycemia in Children with Type 1 Diabetes Mellitus

6thAnnual Symposium on Self-Monitoring of Blood Glucose (SMBG) Applications and Beyond, April 25–27, 2013, Riga, Latvia

Contact Info

Product

Resources

About

6^thAnnual Symposium on Self-Monitoring of Blood Glucose (SMBG) Applications and Beyond, April 25–27, 2013, Riga, Latvia